De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BioRestorative Therapies Beheer

Beheer criteriumcontroles 2/4

De CEO BioRestorative Therapies' is Lance Alstodt, benoemd in Nov2020, heeft een ambtstermijn van 3.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.25M, bestaande uit 38.2% salaris en 61.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.48% van de aandelen van het bedrijf, ter waarde € 270.17K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 6 jaar.

Belangrijke informatie

Lance Alstodt

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris	38.2%
Dienstverband CEO	3.9yrs
Eigendom CEO	2.5%
Management gemiddelde ambtstermijn	3.9yrs
Gemiddelde ambtstermijn bestuur	6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Lance Alstodt's beloning veranderd ten opzichte van BioRestorative Therapies's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$4m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$1m	US$479k	-US$10m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$452k	US$400k	-US$13m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$34m
Mar 31 2022	n/a	n/a	-US$33m
Dec 31 2021	US$21m	US$275k	-US$44m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$26m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$64k	US$64k	-US$11m
Sep 30 2020	n/a	n/a	-US$7m
Jun 30 2020	n/a	n/a	-US$11m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$350k	US$350k	-US$15m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$750k	US$73k	-US$13m

Compensatie versus markt: De totale vergoeding ($USD 1.25M ) Lance } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 503.65K ).

Compensatie versus inkomsten: De vergoeding van Lance is gestegen terwijl het bedrijf verliesgevend is.

CEO

Lance Alstodt (53 yo)

3.9yrs

Tenure

US$1,254,167

Compensatie

Mr. Lance Alstodt serves as President, Chief Executive Officer and Chairman of the Board at BioRestorative Therapies, Inc. since November 16, 2020 and also served as Executive Vice President & Chief Strate...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Lance Alstodt	Chairman of the Board	3.9yrs	US$1.25m	2.48% $ 252.1k
Robert Kristal	Chief Financial Officer	2.9yrs	US$618.12k	0.12% $ 11.7k
Francisco Silva	Chief Scientist	3.9yrs	US$1.20m	2.43% $ 246.3k
Robert Paccasassi	Vice President of Quality Assurance & Regulatory Compliance	9.1yrs	US$287.85k	geen gegevens
Wayne Olan	Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board	6.4yrs	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 9OF wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Lance Alstodt	Chairman of the Board	3.9yrs	US$1.25m	2.48% $ 252.1k
Francisco Silva	Chief Scientist	3.9yrs	US$1.20m	2.43% $ 246.3k
Wayne Olan	Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board	10.5yrs	geen gegevens	geen gegevens
Wayne Marasco	Chairman of Scientific Advisory Board	12.1yrs	geen gegevens	geen gegevens
Joy Cavagnaro	Member of Scientific Advisory Board	9.7yrs	geen gegevens	geen gegevens
Harvinder Sandhu	Member of Scientific Advisory Board	6yrs	geen gegevens	geen gegevens
Patrick Williams	Independent Director	2.9yrs	US$120.00k	0% $ 0
David Rosa	Independent Director	2.9yrs	US$120.00k	0% $ 0
Nickolay Kukekov	Independent Director	3.6yrs	US$120.00k	0% $ 0
Jason Lipetz	Member of Scientific Advisory Board	6.3yrs	geen gegevens	geen gegevens
Christopher Plastaras	Member of Scientific Advisory Board	6yrs	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 9OF wordt beschouwd als ervaren (gemiddelde ambtstermijn 6 jaar).

BioRestorative Therapies Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

BioRestorative Therapies, Inc., Annual General Meeting, Sep 19, 2024

BioRestorative Therapies, Inc., Annual General Meeting, Sep 13, 2023

High number of new and inexperienced directors

BioRestorative Therapies, Inc., Annual General Meeting, Nov 03, 2022

High number of new and inexperienced directors

Insider recently bought €240k worth of stock

Recent updates

Second quarter 2024 earnings released: US$0.50 loss per share (vs US$0.77 loss in 2Q 2023)

BioRestorative Therapies, Inc., Annual General Meeting, Sep 19, 2024

BioRestorative Therapies, Inc. to Report Q2, 2024 Results on Aug 13, 2024

BioRestorative Therapies, Inc. Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies, Inc. announced delayed 10-Q filing

BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity

BioRestorative Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

BioRestorative Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Full year 2023 earnings released: US$3.42 loss per share (vs US$5.11 loss in FY 2022)

New major risk - Shareholder dilution

BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting

New major risk - Share price stability

BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

Third quarter 2023 earnings released: US$0.64 loss per share (vs US$1.28 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.77 loss per share (vs US$1.29 loss in 2Q 2022)

BioRestorative Therapies, Inc., Annual General Meeting, Sep 13, 2023

Biorestorative Therapies Inc. Receives License from New York State

BioRestorative Therapies, Inc. announced that it expects to receive $2.07565 million in funding

BioRestorative Therapies, Inc. Receives Unanimous Recommendation to Proceed in Its Phase 2 Clinical Trial for Chronic Lumbar Disc Disease, BRTX-100

BioRestorative Therapies, Inc. Receives Notice of Allowance by the Japanese Patent and Trademark Office for Patent Application Related to Its Thermostem Program

First quarter 2023 earnings released: US$1.53 loss per share (vs US$1.37 loss in 1Q 2022)

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Phase 2 Clinical Trial

Full year 2022 earnings released: US$5.11 loss per share (vs US$37.30 loss in FY 2021)

Biorestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to Its Thermostem(R) Program

BioRestorative Therapies Inc. Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem Targeting Polycystic Ovary Syndrome as an Indication

Third quarter 2022 earnings released: US$1.28 loss per share (vs US$4.99 loss in 3Q 2021)

High number of new and inexperienced directors

BioRestorative Therapies, Inc., Annual General Meeting, Nov 03, 2022

Second quarter 2022 earnings released: US$1.29 loss per share (vs US$5.11 loss in 2Q 2021)

BioRestorative Therapies, Inc. Announces First Patient Enrolled for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

Biorestorative Therapies, Inc. Announces Clinical Trial Contract with Second Site for the Company’S Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (Cldd)

BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

First quarter 2022 earnings released: US$1.37 loss per share (vs US$21.45 loss in 1Q 2021)

High number of new and inexperienced directors

BioRestorative Therapies, Inc. Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

Insider recently bought €240k worth of stock

Full year 2021 earnings released: US$37.30 loss per share (vs US$28.56 loss in FY 2020)

Biorestorative Therapies Announces It Has Initiated Its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

Forecast to breakeven in 2024

High number of new and inexperienced directors

BioRestorative Therapies, Inc. Announces Filing of Ten Patent Applications Related to its BRTX-100 Program

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$4.99 loss per share (vs US$2.10 loss in 3Q 2020)

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd